FDA Designates Orphan Status for Pharmacyclics (PCYC) CLL Treatment
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Join SI Premium – FREE
The FDA has designated Orphan Drug Status for Pharmacyclics (Nasdaq: PCYC) chronic lymphocyctic leukemia treatment.
Here is the link to the FDA site.
Here is the link to the FDA site.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Lazard Global Total Return fund declares $0.1534 monthly distribution
- Nu Skin EVP of global sales takes medical leave
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
